Bayer and Vanderbilt to Speed Up Cardiovascular and Kidney Treatments

Bayer and Vanderbilt University Medical Center (VUMC) have launched a five-year collaboration focused on fast-tracking the development of new therapies for cardiovascular and kidney diseases.

 The medical requirements in these regions are very high and unmet and thus this partnership is even more important.

It will be based on the advanced research platform of the VUMC, including its BioVU repository of DNA and plasma samples, to create useful data that will accelerate the process of finding and developing possible treatments. Bayer will provide its long-standing experience in drug discovery and translational science, whereas VUMC will provide its profound preclinical and clinical experience.

Also Read: How Digital Maturity is Powering Pharma's GMP Evolution

“We are thrilled to partner with VUMC to bring cutting-edge science and real-world data to accelerate the development of innovative treatments,” said Juergen Eckhardt, Head of Business Development and Licensing at Bayer Pharmaceuticals. “This collaboration reflects our shared vision to bring precision medicine to patients faster.”

Ken Holroyd, Vice President for Tech Transfer at VUMC, added, “VUMC’s recognized research faculty and unique data resources will perfectly complement Bayer’s expertise in pharmaceutical discovery, enabling us to transform research into impactful new treatments for patients.”

This strategic alliance highlights the intentions of the two institutions to promote precision medicine and overcome severe health issues in cardiovascular and kidney diseases.